Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Pfizer Japan and Takeda Pharmaceutical launch Xeljanz for RA in Japan

July 30, 2013

New SYK inhibitors synthesized at Roche

July 30, 2013

CHMP confirms Xeljanz recommendation

July 26, 2013

FDA advisory committee votes in favor of Cimzia for active axial spondyloarthritis

July 25, 2013

Transition Therapeutics licenses candidate for osteoarthritis pain from Lilly

July 25, 2013

Protalex continues enrollment in phase Ib trial of PRTX-100 following third interim review

July 24, 2013

Cellular Biomedicine begins phase I trial of adipose-derived mesenchymal progenitor cells

July 24, 2013

Galapagos earns milestone in osteoarthritis alliance with Servier

July 23, 2013

Xoma provides update on development program for gevokizumab

July 23, 2013

Invion initiates phase II trial of INV-103 in lupus

July 22, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...